(1,4-diazabicyclo[3.2.2]nonan-4-yl)(3-(4-(trifluoromethyl)-1H-pyrazol-1-yl)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)methanone Hydrochloride

ID: ALA5275403

Chembl Id: CHEMBL5275403

Max Phase: Preclinical

Molecular Formula: C18H22ClF3N6O2

Molecular Weight: 410.40

Names and Identifiers

Canonical SMILES:  Cl.O=C(N1CCN2CCC1CC2)n1nc(-n2cc(C(F)(F)F)cn2)c2c1COCC2

Standard InChI:  InChI=1S/C18H21F3N6O2.ClH/c19-18(20,21)12-9-22-26(10-12)16-14-3-8-29-11-15(14)27(23-16)17(28)25-7-6-24-4-1-13(25)2-5-24;/h9-10,13H,1-8,11H2;1H

Standard InChI Key:  SGWGAPZBWBNLGK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 410.40

Molecular Weight (Monoisotopic): 410.1678

AlogP: 1.91

#Rotatable Bonds: 1

Polar Surface Area: 68.42

Molecular Species: NEUTRAL

HBA: 7

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 7.78

CX LogP: 0.96

CX LogD: 0.43

Aromatic Rings: 2

Heavy Atoms: 29

QED Weighted: 0.72

Np Likeness Score: -1.00

References

1. Roecker AJ, Schirripa KM, Loughran HM, Tong L, Liang T, Fillgrove KL, Kuo Y, Bleasby K, Collier H, Altman MD, Ford MC, Drolet RE, Cosden M, Jinn S, Hatcher NG, Yao L, Kandebo M, Vardigan JD, Flick RB, Liu X, Minnick C, Price LA, Watt ML, Lemaire W, Burlein C, Adam GC, Austin LA, Marcus JN, Smith SM, Fraley ME..  (2023)  Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's Disease.,  14  (2.0): [PMID:36793422] [10.1021/acsmedchemlett.2c00441]

Source

Source(1):

• Scientific Literature